Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 1/20 | 0.61 |
| ▸ | ADH1C | P00326 | 1/20 | 0.61 |
| ▸ | ADH1A | P07327 | 1/20 | 0.61 |
| ▸ | ADH7 | P40394 | 1/20 | 0.61 |
| ▸ | TGM2 | P21980 | 1/20 | 0.48 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | AGER | Q15109 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8763196 | 0.88 | ADH1B (0.76) | ADH1BADH1CADH1AADH7LMNA | |
| SCHEMBL8763263 | 0.81 | ADH1B (0.67) | ADH1BADH1CADH1AADH7LMNA | |
| SCHEMBL2595668 | 0.78 | TAAR1 (0.55) | LMNACYP1A2CYP2D6CYP2C19CA12 | |
| SCHEMBL8151807 | 0.78 | PYCR1 (0.64) | TGM2PYCR1LMNACYP1A2CYP2D6 | |
| SCHEMBL17503962 | 0.77 | ADH1B (0.61) | ADH1BADH1CADH1AADH7CYP1A2 | |
| SCHEMBL1486309 | 0.77 | ADH1B (0.61) | ADH1BADH1CADH1AADH7LMNA | |
| SCHEMBL5221625 | 0.77 | ADH1B (0.61) | ADH1BADH1CADH1AADH7ALDH1A1 | |
| SCHEMBL4633463 | 0.77 | ADH1B (0.61) | ADH1BADH1CADH1AADH7LMNA | |
| SCHEMBL43651 | 0.77 | ADH1B (0.61) | ADH1BADH1CADH1AADH7ALDH1A1 | |
| SCHEMBL513192 | 0.77 | ADH1B (0.61) | ADH1BADH1CADH1AADH7CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115043750-B | Method for preparing formamide by low pressure | 中国科学院山西煤炭化学研究所 | 2023-12-26 | — | — | CN | disclosed |
| CN-115043750-A | Method for preparing formamide under low pressure | 中国科学院山西煤炭化学研究所 | 2022-09-13 | — | — | CN | disclosed |
| WO-2020249821-A1 | NOVEL ARGINASE INHIBITORS | RIJKSUNIVERSITEIT GRONINGEN (NL) | 2020-12-17 | — | — | WO | disclosed |
| US-20180093981-A1 | 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors | GENZYME CORPORATION | 2018-04-05 | — | — | US | disclosed |
| US-20170253614-A1 | HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS | CHANGZHOU YINSHENG PHARMACEUTICAL CO., LTD. (CN) | 2017-09-07 | — | — | US | disclosed |
| US-20170253614-A1 | HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS | CHANGZHOU YINSHENG PHARMACEUTICAL CO., LTD. (CN) | 2017-09-07 | — | — | US | disclosed |
| US-9744153-B2 | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2017-08-29 | — | — | US | disclosed |
| US-9745294-B2 | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2017-08-29 | — | — | US | disclosed |
| US-20140371198-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2014-12-18 | — | — | US | disclosed |
| US-8759334-B2 | Compounds useful for the treatment of metabolic and inflammatory diseases | GALAPAGOS NV (BE) | 2014-06-24 | — | — | US | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-8268754-B2 | Substituted dihydroazole compound and pest control agent | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-09-18 | — | — | US | disclosed |
| WO-2012098033-A1 | AZETIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF METABOLIC AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2012-07-26 | — | — | WO | disclosed |
| US-20100298558-A1 | SUBSTITUTED DIHYDROAZOLE COMPOUND AND PEST CONTROL AGENT | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-11-25 | — | — | US | disclosed |
| EP-2230230-A1 | SUBSTITUTED DIHYDROAZOLE COMPOUND AND PEST CONTROL AGENT | Nissan Chemical Industries, Ltd. (JP) | 2010-09-22 | — | — | EP | disclosed |
| US-20100099676-A1 | SULFONYLUREA DERIVATIVE CAPABLE OF SELECTIVELY INHIBITING MMP-13 | SHIONOGI & CO., LTD. (JP) | 2010-04-22 | — | — | US | disclosed |
| EP-2128134-A1 | SULFONYLUREA DERIVATIVE CAPABLE OF SELECTIVELY INHIBITING MMP-13 | Shionogi&Co., Ltd. (JP) | 2009-12-02 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | ADH1B 281/4885ADH1C 285/4885ADH1A 494/4885 |
| US-20170253614-A1 | HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS | HAVCR2, HCCS, LIPC | ADH1B 1060/4885ADH1C 395/4885ADH1A 659/4885 |
| US-20140371198-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC AND INFLAMMATORY DISEASES | GOT2, GPR119, PC | ADH1B 487/4885ADH1C 1915/4885ADH1A 2316/4885 |
| US-20100099676-A1 | SULFONYLUREA DERIVATIVE CAPABLE OF SELECTIVELY INHIBITING MMP-13 | MMP13, MMP3, MMP26 | ADH1B 2296/4885ADH1C 1803/4885ADH1A 2146/4885 |
| US-20100298558-A1 | SUBSTITUTED DIHYDROAZOLE COMPOUND AND PEST CONTROL AGENT | H1-0, H1-2, H1-4 | ADH1B 1701/4885ADH1C 191/4885ADH1A 564/4885 |
| US-20180093981-A1 | 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors | ASAH2, GBA1, GAA | ADH1B 703/4885ADH1C 462/4885ADH1A 1030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.